CoChat

Population-Based Assessment of a Biomarker-Based Screening Pathway to Aid Diagnosis of Monogenic Diabetes in Young-Onset Patients

Open access

The DOI matches its Crossref record; 31 of the 34 references it cites were found in a registry or an index.

Abstract

OBJECTIVE Monogenic diabetes, a young-onset form of diabetes, is often misdiagnosed as type 1 diabetes, resulting in unnecessary treatment with insulin. A screening approach for monogenic diabetes is needed to accurately select suitable patients for expensive diagnostic genetic testing. We used C-peptide and islet autoantibodies, highly sensitive and specific biomarkers for discriminating type 1 from non–type 1 diabetes, in a biomarker screening pathway for monogenic diabetes. RESEARCH DESIGN AND METHODS We studied patients diagnosed at age 30 years or younger, currently younger than 50 years, in two U.K. regions with existing high detection of monogenic diabetes. The biomarker screening pathway comprised three stages: 1) assessment of endogenous insulin secretion using urinary C-peptide/creatinine ratio (UCPCR); 2) if UCPCR was ≥0.2 nmol/mmol, measurement of GAD and IA2 islet autoantibodies; and 3) if negative for both autoantibodies, molecular genetic diagnostic testing for 35 monogenic diabetes subtypes. RESULTS A total of 1,407 patients participated (1,365 with no known genetic cause, 34 with monogenic diabetes, and 8 with cystic fibrosis–related diabetes). A total of 386 out of 1,365 (28%) patients had a UCPCR ≥0.2 nmol/mmol, and 216 out of 386 (56%) were negative for GAD and IA2 and underwent molecular genetic testing. Seventeen new cases of monogenic diabetes were diagnosed (8 common Maturity Onset Diabetes of the Young [Sanger sequencing] and 9 rarer causes [next-generation sequencing]) in addition to the 34 known cases (estimated prevalence of 3.6% [51/1,407] [95% CI 2.7–4.7%]). The positive predictive value was 20%, suggesting a 1-in-5 detection rate for the pathway. The negative predictive value was 99.9%. CONCLUSIONS The biomarker screening pathway for monogenic diabetes is an effective, cheap, and easily implemented approach to systematically screening all young-onset patients. The minimum prevalence of monogenic diabetes is 3.6% of patients diagnosed at age 30 years or younger.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc17-0224

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Research works printed but not linked: 1

  1. Cole, 1980, Basic issues in population screening for cancer, J Natl Cancer Inst, 64, 1263

Cited by

Metadata

Authors
Shields, B. M., Shepherd, M., Hudson, M., McDonald, T. J., Colclough, K., Peters, J., Knight, B., Hyde, C., Ellard, S., Pearson, E. R., & Hattersley, A. T.
Affiliations
  • University of Exeter (GB)
  • Royal Devon & Exeter NHS Foundation Trust (GB)
  • University of Dundee (GB)
Corresponding author
Hattersley, Andrew T.
Venue
Diabetes Care
Published
2017-07-11
Volume
40
Issue
8
Pages
1017-1025
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2612062408
Cited by
151
References
34
Citations by year
2026: 11 · 2025: 10 · 2024: 14 · 2023: 12 · 2022: 22 · 2021: 19 · 2020: 22 · 2019: 20 · 2018: 20 · 2017: 1
FWCI
11.41
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion)
  • PubMed (publishedVersion)
  • Discovery Research Portal (University of Dundee) (publishedVersion, other-oa)
  • PubMed Central (acceptedVersion)
  • Open Research Exeter (University of Exeter) (acceptedVersion)
  • Royal Devon and Exeter Research Repository (Royal Devon and Exeter) (acceptedVersion)
  • Figshare (submittedVersion)
Funders
  • Department of Health
  • Wellcome Trust (HICF-1009-041, WT-091985)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
monogenic diabetes, young-onset diabetes, biomarker screening, islet autoantibodies, glutamic acid decarboxylase antibodies, maturity-onset diabetes of the young, cystic fibrosis-related diabetes, genetic testing, prevalence, screening pathway
MeSH terms
Adult, Autoantibodies, C-Peptide, Creatinine, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Female, United Kingdom, Humans, Insulin, Male, Middle Aged, Sensitivity and Specificity, Cohort Studies, Biomarkers, Prevalence, Sequence Analysis, DNA, Hepatocyte Nuclear Factor 1-alpha, Hepatocyte Nuclear Factor 4, High-Throughput Nucleotide Sequencing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.